Where do we stand in developing radionuclides against molecular markers overexpressed on breast cancer (BC) cells such as EGFR-family members?
Willy Vangu
nuclear medicine, Johannesburg, South Africa
nuclear medicine, Johannesburg, South Africa
Economics issues and breast cancer
Jean Jacques ZAMBROWSKI
Economist, Paris, France
Thoughts on DESTINY-Breast04 for HER2-low metastatic breast cancer.
Joseph GLIGOROV
Oncologist, Paris, France
Can you explain free flaps technique reconstruction?
Yazan MASANNAT
surgeon, London, UK
MRI Imaging bone metastatic assessment.
Yvonne MARATOS
Radiologist, Cannes, France
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.